An industry survey looks at changing attitudes and challenges in digital innovation for clinical research. Uptake is slow but steady. Rob Ellison | 03/31/2025 | 7 min read | Hot Topic Technological innovations and digital disruptions have a long history in clinical research. We often push boundaries of what’s possible to enable better, faster drug development to bring therapies to patients. However, this innovation push is pulled back by a necessary caution because, at the end of the day, patient safety, data integrity and regulatory compliance are paramount to our operations. Icon’s digital disruption survey and the publication of a related white paper (Digital Disruption. Surveying the Industry’s Evolving Landscape) is a follow-on to a similar survey we conducted in 2019, when ideas such as blockchain and organ-on-a-chip were buzzing in the industry. In the time since, we have seen an organic shift in the hype cycle, with some technologies seeing more significant uptake than others. AI, for example, has become more pervasive as a solution to other technological capabilities, such as remote monitoring, and enabled the industry’s current data abundance. We were also interested to see how pandemic-era digital adoptions impacted the overall trajectory of technology in clinical […]
Click here to view original web page at themedicinemaker.com
